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EBioMedicine provides new insights into the pathophysiology of
the inﬂammatory system in Alzheimer's disease (AD). The story de-
scribing the accumulation of aggregated proteins in the AD brain, in-
cluding β-amyloid and tau protein, has been developing since Alois
Alzheimer ﬁrst identiﬁed neuroﬁbrillary tangles with a silver stain
more than 100 years ago. Classically, neuritic plaques composed of
aggregated Aβ peptides accumulate in the neuropil, outside neurons
and glia, while neuroﬁbrillary tangles composed of aggregated tau
accumulate within neurons. The localization of these proteins neces-
sarily focused attention on neuronal dysfunction in AD.
However, all neurodegenerative diseases also suffer from a dysfunc-
tional inﬂammatory response, but the biological basis of this response is
largely unknown. The classic model for the inﬂammatory response
posits the presence of two states:M1, a cytotoxic state, andM2, a regen-
erative state. This simplemodel describingM1 andM2 in ADwas initial-
ly appealing but now appears to insufﬁciently describe the varied
immunological states characteristic of the AD brain. This model appears
to be inadequate because it omits the process of phagocytosis, which
appears to play a very important role in AD.
Recent Genome-wideAssociation Studies have implicated triggering
receptor expressed on myeloid cells 2 (TREM2) and CD33, both of
which regulate microglial phagocytosis, in AD. The signaling pathway
leading from TREM2 plays a key role in the article by Ghosh and
Ghealan. TREM2 couples to TYRO protein tyrosine kinase binding pro-
tein (TYROBP), which then recruits spleen tyrosine kinase (Syk) to the
phosphorylated immunoreceptor tyrosine-based activation motif
(ITAM) of TYROBP, and activates phagocytosis (N'Diaye et al., 2009).
CD33 is also a risk factor for AD, but acts in opposition to TREM2.
CD33 binds to Syk through its immunoreceptor tyrosine-based inhibito-
ry motif (ITIM) domain and inactivate the phagocytic response of mi-
croglia. These studies suggest that TREM2 and CD33 play important
reciprocal roles in regulating the phagocytic function of microglia in
the CNS, with Syk acting as a downstream kinase that mediates the
actions of TREM2 and CD33 on phagocytosis. However the actions ofDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.09.053.
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Enter the article by Ghosh and Ghealen, which highlights a surpris-
ing interaction between Syk and GTPase activating protein binding pro-
tein (G3BP), which binds RNA. RNA binding proteins are a fascinating
group of proteins, several of which have already been genetically linked
to motor neuron degenerative diseases, that regulate RNA metabolism
in the nucleus and cytoplasm. While in the nucleus, RNA binding pro-
teins regulate functions like RNA splicing and transcription. Upon trans-
location to the cytoplasm, they control the localization, transport and
translational activity of mRNA. They do so through a uniquemechanism
mediated by reversible aggregation into macromolecular stress gran-
ules via low complexity, prion-like domains present in most RNA bind-
ing proteins. Normal physiological aggregation in the biology of RNA
binding proteins suggests a provocative connection with the patho-
physiology of neurodegenerative diseases, where pathological protein
aggregation plays a prominent role.
Until now, pathological protein aggregationwas thought to be limit-
ed to within neurons or to the extracellular space. In the current article,
Ghosh andGhealen highlight a pathologicalmicroglial response that oc-
curs after Aβ treatment. They show that treatingmicroglial cellswithAβ
causes formation of persistent, abnormally large G3BP granules. The
ﬁnding of large, potentially pathological G3BP granules is important
because it expands the aggregation story from the classic pathology-
associated aggregates of tau within neurons to include a potentially new
type of pathological aggregate composed of G3BP. The presence of these
large G3BP aggregates is consistent with studies from our group showing
the presence of seemingly pathological accumulations of G3BP in brain
samples from human cases with AD and both human and mouse cases
of tauopathy (Vanderweyde et al., 2012, Vanderweyde et al., 2013).
Ghosh and Ghealen also make the striking observation that phos-
phorylated Syk translocates to G3BP granules after exposure to Aβ.
This suggests a mechanism whereby chronic activation of Syk could
cause microglial dysfunction by Syk sequestration. We still don't know
what is the binding partner of phosphorylated Syk in stress granules,
and how Syk is recruited to them. Moreover, the downstream effects
of Syk translocation to G3BP granules remain to be determined. The au-
thors note that activatedmicroglia show induction of pro-inﬂammatory
cytokines by Aβ, including interferon gamma (IFN-γ), interleukin 1β
(IL-1β) and monocyte chemoattractant protein 1 (MCP-1). These arethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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after Aβ phagocytosis and enhance Aβ accumulation in mouse brains
(Yamamoto et al., 2008, Yamamoto et al., 2005) (Yamamoto et al.,
2007). This study sheds new light on upstreammechanisms of cytokine
production upon Aβ stimulation of microglia, namely through the
Syk-stress granule axis.
The work of Ghosh and Ghealen might also help to elucidate an im-
portant controversy in the inﬂammation ﬁeld:whydoes the response of
microglia to TREM2 inactivation differ between mouse models and
human diseases? Loss of function mutations of TREM2 or TYROBP are
linked to highly inﬂammatory Nasu-Hakola disease in human, whereas
disruption of TREM2 in amyloid precursor protein (APP)-overexpress-
ing mice, a model of AD, results in reduced inﬂammation and Aβ accu-
mulation in mouse brain (Jay et al., 2015). One possibility is the
species-speciﬁc heterogeneity in Syk-associated stress granule com-
plex, which may have contrasting biological outputs dependent on
their molecular conﬁguration. In highlighting the interaction between
Syk and G3BP granules, the work of Ghosh and Ghrealin potentially
opens a new chapter in our understanding of pathophysiological mech-
anisms of inﬂammation and microglia in AD, opening doors to novel
therapies.
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